CYP3A5 gene polymorphism and risk of prostate cancer in a Japanese population.
The CYP3A5 gene (CYP3A5) encodes the cytochrome P450 3A5, which catalyzes the 6beta-hydroxylation of testosterone. We explored association between the CYP3A5 A6986G polymorphism and a risk of prostate cancer in 260 prostate cancer patients, 199 BPH patients and 212 male controls. The CYP3A5 gene polymorphism did not influence significantly a risk of developing of prostate cancer in general. However, compared with males with the GG genotype, those with the AA genotype had a 0.23-fold decreased risk of developing low-grade prostate cancer (P=0.023), and a 0.31-fold decreased risk of developing localized (stages A-C) prostate cancer (P=0.044). The CYP3A5 A6986G polymorphism may be specifically associated with a decreased risk of low-grade or early stage prostate cancer.
Zhenhua
Li
L
Department of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan.
Tsuchiya
Norihiko
N
Narita
Shintaro
S
Inoue
Takamitsu
T
Horikawa
Yohei
Y
Kakinuma
Hideaki
H
Kato
Tetsuro
T
Ogawa
Osamu
O
Habuchi
Tomonori
T
D000368:Aged; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005838:Genotype; D006801:Humans; D007564:Japan; D008297:Male; D011110:Polymorphism, Genetic / Q000235:genetics*; D011471:Prostatic Neoplasms / Q000235:genetics*
D003577:Cytochrome P-450 Enzyme System; C104464:CYP3A protein, human; C510164:CYP3A5 protein, human; D051544:Cytochrome P-450 CYP3A